This is a House of Representatives resolution recognizing a designated day for APOL1-mediated kidney disease AMKD Awareness Day. It expresses support for designating the last Tuesday of April as AMKD Awareness Day and urges the public to become informed about kidney disease and APOL1 related risks.
It also encourages individuals with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations. The resolution does not create enforceable duties or funding; its effect is purely ceremonial and informational, intended to raise awareness and foster dialogue among patients, clinicians, and public health stakeholders.
At a Glance
What It Does
The resolution designates the last Tuesday of April as AMKD Awareness Day and expresses support for raising public awareness about APOL1 mediated kidney disease; it does not authorize funding or impose duties.
Who It Affects
The designation targets the general public, health educators, clinicians, and public health programs, with particular relevance to communities affected by kidney disease and APOL1 risk variants.
Why It Matters
It highlights disparities in kidney disease burdens, elevates attention to APOL1 related risks, and signals a social and educational commitment without creating regulatory obligations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is a non-binding House resolution that designates the last Tuesday of April as AMKD Awareness Day to focus attention on APOL1 mediated kidney disease. It provides background on the prevalence of kidney disease in the United States, the disproportionate impact on Black Americans, and the role of APOL1 gene variants in kidney disease risk.
While the resolution does not create legal duties or authorize funding, it advances public awareness and education by urging people to learn about kidney disease and consider APOL1 genetic testing if they have ancestry from Western or Central Africa. The text frames APOL1 as a genetic risk factor and emphasizes the potential for awareness and proactive health management, rather than mandating clinical actions.
The Five Things You Need to Know
The bill designates the last Tuesday of April as AMKD Awareness Day, The House expresses support for AMKD Awareness Day and related awareness efforts, The resolution cites national kidney disease statistics and dialysis prevalence, It highlights higher risk among Black Americans and APOL1 gene variants, It encourages individuals with Western or Central African ancestry to consider APOL1 genetic testing
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation of AMKD Awareness Day
This section states the House supports designating AMKD Awareness Day and designates the last Tuesday of April for annual recognition. It frames the day as a vehicle to raise awareness about APOL1 mediated kidney disease without creating new requirements for individuals, providers, or institutions.
Public Awareness and Education
This section urges the public to become better informed about kidney disease and APOL1 mediated kidney disease. It positions awareness as a voluntary, informational goal supported by health education efforts rather than a regulatory obligation.
Genetic Testing Encouragement
This section encourages people from Western or Central Africa to consider genetic testing for APOL1 gene mutations as a step toward informed health management. It does not mandate testing or provide funding; it highlights potential benefits of awareness in guiding health conversations with clinicians.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals with APOL1 risk variants and their families, who may gain greater access to information and early awareness about kidney health risks.
- Public health organizations and kidney disease advocacy groups, which can leverage a national awareness day for outreach and education.
- Nephrologists and primary care physicians, who can use heightened awareness to guide patient discussions and preventive care.
- Genetic counselors and testing laboratories, which may see increased engagement in APOL1 related testing discussions.
- Researchers studying APOL1 genetics and kidney disease, who may benefit from greater public attention and patient education.
Who Bears the Cost
- Public health departments may incur minor outreach costs to promote AMKD Awareness Day and associated education.
- Hospitals, clinics, and clinicians may spend time on patient education and awareness activities related to AMKD.
- Nonprofit organizations and advocacy groups may allocate resources for events and information campaigns.
- Educational institutions or programs may need to adapt materials to include AMKD awareness content.
Key Issues
The Core Tension
Raising awareness about a genetic risk factor while avoiding messaging that could lead to stigma, discrimination, or overemphasis on genetics at the expense of broader kidney health determinants; balancing ceremonial advocacy with the absence of funding or mandate.
The resolution is ceremonial in nature and does not authorize funding or impose regulatory requirements. It relies on voluntary education and public outreach to raise awareness about APOL1 mediated kidney disease.
Implementing these awareness efforts would depend on existing channels for health communication and collaboration among health care providers, educators, and patient groups. Potential tensions include ensuring that genetic testing discussions respect privacy and prevent stigmatization, and avoiding the impression that one gene fully determines risk.
Questions remain about how best to translate awareness into constructive health actions without creating unintended incentives or misunderstandings.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.